GBM-Targeted oHSV Armed with Matrix Metalloproteinase 9 Enhances Anti-tumor Activity and Animal Survival

The use of mutant strains of oncolytic herpes simplex virus (oHSV) in early-phase human clinical trials for the treatment of glioblastoma multiforme (GBM) has proven safe, but limited efficacy suggests that more potent vector designs are required for effective GBM therapy. Inadequate vector performa...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Mol Ther Oncolytics
Main Authors: Sette, Paola, Amankulor, Nduka, Li, Aofei, Marzulli, Marco, Leronni, Daniela, Zhang, Mingdi, Goins, William F., Kaur, Balveen, Bolyard, Chelsea, Cripe, Timothy P., Yu, Jianhua, Chiocca, E. Antonio, Glorioso, Joseph C., Grandi, Paola
Formato: Artigo
Idioma:Inglês
Publicado: American Society of Gene & Cell Therapy 2019
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6926261/
https://ncbi.nlm.nih.gov/pubmed/31890868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.omto.2019.10.005
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares